

Amendments to the Specification:

Please replace the paragraph at page 101, from line 7 through line 20, with the following paragraph:

-- Preferably, the polynucleotide, polypeptide, compound or vector, etc described here may be delivered into cells by being conjugated with, joined to, linked to, fused to, or otherwise associated with a protein capable of crossing the plasma membrane and/or the nuclear membrane (i.e., a membrane translocation sequence). Preferably, the substance of interest is fused or conjugated to a domain or sequence from such a protein responsible for the translocational activity. Translocation domains and sequences for example include domains and sequences from the HIV-1-trans-activating protein (Tat), *Drosophila* Antennapedia homeodomain protein and the herpes simplex-1 virus VP22 protein. In a highly preferred embodiment, the substance of interest is conjugated with penetratin protein or a fragment of this. Penetratin comprises the sequence RQIKIWFQNRRMKWKK (SEQ ID NO: 1) and is described in Derossi et al., 1994, *J. Biol. Chem.* 269:10444-50; use of penetratin-drug conjugates for intracellular delivery is described in WO 00/01417. Truncated and modified forms of penetratin may also be used, as described in WO 00/2927. --

Please replace the paragraph at page 146, from line 11 through line 13, with the following paragraph:

-- MS

Sense : UGAGAAUGUGAUGC CGCGU CCTT (SEQ ID NO: 2)

Antisense: GACGCGCAUCACAUUCUCATT (SEQ ID NO: 3) --

Please replace the paragraph at page 147, from line 10 through line 12, with the following paragraph:

-- Survivin (Survivin B, SurB, SURB, SUR)

Serial No.: 10/764,238

Docket No.: 8912/2012

Page 4

Sense : GAACUGGCCUUCUUGGAGtt (SEQ ID NO: 4)

Antisense: CUCCAAGAAGGGCCAGUUCtt (SEQ ID NO: 5) --

Please replace the paragraph at page 147, from line 15 through line 17, with the following paragraph:

-- PI3KR1

Sense : AUGAUCGAUGUGCACGUUUtt (SEQ ID NO: 6)

Antisense: AAACGUGCACAUCAUCGAUCAUtt (SEQ ID NO: 7) --

Please replace the paragraph at page 147, from line 19 through line 21, with the following paragraph:

-- BCL2

Sense : GUACAUCCAUUAUAAGCUGtt (SEQ ID NO: 8)

Antisense: CAGCUUAUAAUGGAUGGUACtt (SEQ ID NO: 9) --

Please replace the paragraph at page 148, from line 1 through line 3, with the following paragraph:

-- c-Raf (CRAF)

Sense : UAGUUCAGCAGUUUGGUAtt (SEQ ID NO: 10)

Antisense: UAGCCAAACUGCUGAACUAtt (SEQ ID NO: 11) --

Please replace the paragraph at page 150, from line 13 through line 15, with the following paragraph:

-- QPCR Primers, designed by MWG Biotech as described previously, are as follows.

<b>Gene</b>	<b>Forward Primer (5'-3')</b>	<b>Reverse Primer (5'-3')</b>
OAS1 (NM_002534)	GCGCCCCACCAAGCTCAAGA (SEQ ID NO: 12)	GTCCGAAATCCCTGGGCTGTGTT (SEQ ID NO: 13)
GBP1 (NM_002503)	TATGGTGGTGGTGGCAATTG TGG (SEQ ID NO: 14)	ACGGCCAGGGCGAAGATCC (SEQ ID NO: 15)

--

Please replace Table 4 at page 182, with the following Table 4:

-- TABLE 4 QPCR primers for Target Genes:

<b>Gene</b>	<b>Forward Primer (5'-3')</b>	<b>Reverse Primer (5'-3')</b>
MAK	GGGAGCTGGTGGCCATCAAAA (SEQ ID NO: 16)	TGGATAAAAGCCAGCCCTTGCA (SEQ ID NO: 17)
GPR86	TGAGCGGTGCCCGCAGAGACA (SEQ ID NO: 18)	CAGGGTGCCAGGTGTGAGTCAGA (SEQ ID NO: 19)
PCTAIRE	GCCGCTCAGCCGCATGTCC (SEQ ID NO: 20)	GGCGCTCCCTCCTCGTGCTC (SEQ ID NO: 21)
GRAF	CAGCGAACGGGAAGTTGCAGA (SEQ ID NO: 22)	CTTCCTTGGCAGCCCCGATC (SEQ ID NO: 23)
MPSK1	CGCGCTGTGTGTCTGCTCTCG (SEQ ID NO: 24)	GCGAAGGATGTTGGGGTGATTG (SEQ ID NO: 25)
RBS5PK	GCCGCCAAAAAAAGTGCCTGC (SEQ ID NO: 26)	TCCTTCATCATTGCACTCCTGGC (SEQ ID NO: 27)
TLK2	GCAGTTCCC GCCAAAGCCAGTA (SEQ ID NO: 28)	GGACGCCAGAGGTTGATGC (SEQ ID NO: 29)
EK1	CGGGCCGGGCTCAGTTCA (SEQ ID NO: 30)	CGGCGGAGACTACCACACGA (SEQ ID NO: 31)
MKNK	CAAGCAGGGCACAGTCGGAGTAG (SEQ ID NO: 32)	CGGCTGGCTTCTCGCTCATLG (SEQ ID NO: 33)
NTKL	GGCAGCCCCGTGTCCATCTTC (SEQ ID NO: 34)	CCAGCCTCCACTCTCGCCTTGA (SEQ ID NO: 35)
CDC42	CAAAGCGAGAACGGCATAACGAG (SEQ ID NO: 36)	CCGGGCATCTTCTCGTCACTG (SEQ ID NO: 37)

Serial No.: 10/764,238

Docket No.: 8912/2012

Page 6

RBSK	GGCGCGTCTGGGAACC (SEQ ID NO: 38)	AGCCGAGCAGCTGGACACACTG (SEQ ID NO: 39)
EDG6	CGGCGGTCAACCCCATCATCT (SEQ ID NO: 40)	CCCGCATCCGAAAGCTGAGC (SEQ ID NO: 41)
CNK/PRK	CGCGGACCTGAGCTGGAGATG (SEQ ID NO: 42)	TGGCGACGCGGCTCTGC (SEQ ID NO: 43)
MAPKK5	CGGGCCGCAGTTACTCTTCAGG (SEQ ID NO: 44)	CCGGCCCCGAGTATTCACCTCA (SEQ ID NO: 45)
P14KB	CGGAGGGGGTCGGGAAC (SEQ ID NO: 46)	GCGGCCCATCTCATCTTC (SEQ ID NO: 47)
FLT4	TGCCGTGAACCCCATCGAGAG (SEQ ID NO: 48)	CGTGGACAGGTTGAGGCGGTAC (SEQ ID NO: 49)
PSKH1	CCCGAGCCACCCAAGGATGTC (SEQ ID NO: 50)	GGCCCTGCGTGGTGGTCTGA (SEQ ID NO: 51)
ITPKC	AGCCGGACAGCAGCGACCT (SEQ ID NO: 52)	TTTGCTTGGGCCTCTCGGTCTC (SEQ ID NO: 53)
ROCK	GTGGGCTTGGGAAACGCTC (SEQ ID NO: 54)	TCTGCATTGGAGCTAGTTCTGTTAT C (SEQ ID NO: 55)

--  
Please replace Table 8 at page 186, with the following Table 8:

--

**Table 8. Q-PCR primers for target genes and relevant control genes.**

Gene	Forward Primer (5' to 3') <sup>1</sup>	Reverse Primer (5' to 3') <sup>1</sup>	Conc. <sup>2</sup>
GRAF	GATAGTCCGCACTTCCG (SEQ ID NO: 56)	GAGTGACTTCCGTCCTT (SEQ ID NO: 57)	100 nM
ULK1	GACTTCCAGGAAATGGCT (SEQ ID NO: 58)	AGAGCCTGATGGTGTCTC (SEQ ID NO: 59)	100 nM
EKI	CGTCGTGGTAGTCTC (SEQ ID NO: 60)	GATGCTCCTCCTGATCCT (SEQ ID NO: 61)	100 nM
ROCK1	GCATAAATCCACCAGGAA (SEQ ID NO: 62)	ATGTCCTTCTTCCCAG (SEQ ID NO: 63)	100 nM
NTKL	TACCTCAAGGCGAGAGTG (SEQ ID NO: 64)	CAGTCGTTGACCAGGAAG (SEQ ID NO: 65)	100 nM
RBSK	ATACGGAGGATCTGAGGG (SEQ ID NO: 66)	TCCAAAGAAGTTGCTGGA (SEQ ID NO: 67)	100 nM
DAGK	GGAAGGTGACGCTCACCAAG (SEQ ID NO: 68)	ACATGAAATTGCAGACGTCGC (SEQ ID NO: 69)	200 nM

Serial No.: 10/764,238

Docket No.: 8912/2012

Page 7

ITPKC	CAGACGGACAGACTGAGC (SEQ ID NO: 70)	TCCATTCTAGATGCGTCC (SEQ ID NO: 71)	100 nM
UKH	TGCAGTACGATGTGCTTG (SEQ ID NO: 72)	CAGCACTTCCTGGTCTG (SEQ ID NO: 73)	100 nM
BAI2	CCTGCTGAGGCCGATTG (SEQ ID NO: 74)	TTTCACTTCGGTTCCTCTTCC (SEQ ID NO: 75)	100 nM
GPR12	AAGGTCAATTAAAGCGGGCTG (SEQ ID NO: 76)	TCTGGCTCTACGGCAGGAAC (SEQ ID NO: 77)	200 nM
GPR86	AGGTGACACTGGAAGCAA (SEQ ID NO: 78)	CACTGTGTAGAGGGCTGG (SEQ ID NO: 79)	100 nM
Bcl2	CACGCTGGGAGAACAGGGT (SEQ ID NO: 80)	CACATCTCCCGCATCCCCA (SEQ ID NO: 81)	100 nM
Survivin B	TCAAGGACCACCGCATCTCT (SEQ ID NO: 82)	CAGTGGATGAAGCCAGCCTC (SEQ ID NO: 83)	100 nM
GAPDH	CGACCACTTGTCAAGCTCA (SEQ ID NO: 84)	GGGTCTTACTCCTGGAGGC (SEQ ID NO: 85)	100 nM

<sup>1</sup>Primers are synthesised by MWG-Biotech. <sup>2</sup>The final concentration of each primer in a Q-PCR reaction.

--  
Please replace Table 9 at page 187, with the following Table 9:

--  
**Table 9. Sequence of siRNA oligonucleotides.**

Gene	Sense Oligonucleotide (5'-3')	Antisense Oligonucleotide (5'-3')
GRAF	GCGGAAGUUUGCAGAUUCCtt (SEQ ID NO: 86)	GGAAUCUGCAAACUUCCGCtt (SEQ ID NO: 87)
ULK1 <sup>1</sup>	GGAACUGAACACAUGAAAACtt (SEQ ID NO: 88)	GUUUUCAUGUUUCAGUUCCtt (SEQ ID NO: 89)
EKI	GCACUGGAUCCAAAGCAUGtt (SEQ ID NO: 90)	CAUGCUUJUGGAUCCAGUGCtt (SEQ ID NO: 91)
ROCK	UACAUGCCUGGUGGAGAUt (SEQ ID NO: 92)	GAUCUCCACCAGGCAUGUAtt (SEQ ID NO: 93)
NTKL	UGUGGGAGCUGAUGAAGCACtt (SEQ ID NO: 94)	GUGCUUCAUCAGCUCCACAtt (SEQ ID NO: 95)
RBSK	CGUCCUGGAGUGACAAAUtt (SEQ ID NO: 96)	CAUUUGUCACUCCAGGACGtt (SEQ ID NO: 97)
DAGK <sup>1</sup>	GGCUGCACAACAAGGGUGUtt (SEQ ID NO: 98)	ACACCCUUGUJUGUGCAGCCtg (SEQ ID NO: 99)
ITPKC	GUCCUGGGCUGAUACCUCtt (SEQ ID NO: 100)	GAGGUUAUCAGCCCAGGACtt (SEQ ID NO: 101)

UKH	AGCGCAAGACACUCUGUGGtt <u>(SEQ ID NO: 102)</u>	CCACAGAGUGUCUUGCGCUtt <u>(SEQ ID NO: 103)</u>
BAI2 <sup>1</sup>	GGACCUGUUUGGUACCAUCtt <u>(SEQ ID NO: 104)</u>	GAUGGUAGGAAAGAGGUCCtg <u>(SEQ ID NO: 105)</u>
GPR12 <sup>1</sup>	GGACGGUCACGUUUACCUAtt <u>(SEQ ID NO: 106)</u>	UAGGUAAAACGUGACCGUCCtc <u>(SEQ ID NO: 107)</u>
GPR86	AAACACUUUUGGUGGCCGACtt <u>(SEQ ID NO: 108)</u>	GUCGGCCACCAAAGUGUUUtt <u>(SEQ ID NO: 109)</u>

<sup>1</sup>siRNA sequences designed and synthesised by Ambion.

-- Please replace Table 11 at page 188, with the following Table 11:

-- TABLE 11

Gene	Sense Oligonucleotide (5'-3')	Antisense Oligonucleotide (5'-3')
MAK	GAAGCCAAGCAUGGGUGGUUtt <u>(SEQ ID NO: 110)</u>	AACACCCAUGCUUGGCUUCtt <u>(SEQ ID NO: 111)</u>
GPR86	AAACACUUUUGGUGGCCGACtt <u>(SEQ ID NO: 112)</u>	GUCGGCCACCAAAGUGUUUtt <u>(SEQ ID NO: 113)</u>
PCTAIRE	GUCAGUGCCCACAAAGACUtt <u>(SEQ ID NO: 114)</u>	AGUCUUUGUGGGCACUGACtt <u>(SEQ ID NO: 115)</u>
GRAF	GCGGAAGUUUGCAGAUUCCtt <u>(SEQ ID NO: 116)</u>	GGAAUCUGCAAACUUCCGtt <u>(SEQ ID NO: 117)</u>
MPSK1	GGGUUAUGCCCACAGAGACtt <u>(SEQ ID NO: 118)</u>	GUCUCUGUGGGCAUAACCCtt <u>(SEQ ID NO: 119)</u>
MPSK1seq2 <sup>1</sup>	GCCGACAUGCAUCGCCUCUtt <u>(SEQ ID NO: 120)</u>	AGAGGCGAUGCAUGUCGGCtt <u>(SEQ ID NO: 121)</u>
RBS6PK	CGUCCUGGAGUGACAAUAGtt <u>(SEQ ID NO: 122)</u>	CAUUUGUCACUCCAGGACGtt <u>(SEQ ID NO: 123)</u>
TLK2A <sup>2</sup>	GUGUUCCACCAAGUUGCACGtt <u>(SEQ ID NO: 124)</u>	CGUGCAACUGGUGGAACACtt <u>(SEQ ID NO: 125)</u>
TLK2B <sup>2</sup>	GAUGGCGUGUAGAGAUAAAGtt <u>(SEQ ID NO: 126)</u>	CUUAUCUCUACACGCCAUCtt <u>(SEQ ID NO: 127)</u>
EKI1	GCACUGGAUCCAAAGCAUGtt <u>(SEQ ID NO: 128)</u>	CAUGCUUUGGAUCCAGUGCtt <u>(SEQ ID NO: 129)</u>
MKNK	UACAUGGCCCCUGAGGUAGtt <u>(SEQ ID NO: 130)</u>	CUACCUCAGGGGCCAUGUAtt <u>(SEQ ID NO: 131)</u>
MKNKseq2 <sup>1</sup>	AUUGCAAGGAGGUUCCAUCCtt <u>(SEQ ID NO: 132)</u>	GAUGGAACCUCCUUGCAAUtt <u>(SEQ ID NO: 133)</u>

NTKL	UGUGGAGCUGAUGAAGCACtt (SEQ ID NO: 134)	GUGCUUCAUCAGCUCCACAtt (SEQ ID NO: 135)
CDC42	GCUCAGCUUGAUGAUGCUGtt (SEQ ID NO: 136)	CAGCAUCAUCAAGCUGAGCtt (SEQ ID NO: 137)
RBSK	GACCUUCCGCUUACUCUGUtt (SEQ ID NO: 138)	ACAGAGUAAGCGGAAGGUtt (SEQ ID NO: 139)
EDG6	CAUCACCGCUGAGUGACCUGtt (SEQ ID NO: 140)	CAGGUCACUCAGCGUGAUGtt (SEQ ID NO: 141)
CNK/PRK	UCGUAGUGCUUGUACUUACtt (SEQ ID NO: 142)	GUAAGUACAAGCACUACGAtt (SEQ ID NO: 143)
CNK/PRKseq2 <sup>1</sup>	CAGAAAGACUGUGCACUACtt (SEQ ID NO: 144)	GUAGUGGCACAGUCUUUCUGtt (SEQ ID NO: 145)
MAPKK5	GAGGACAGGUUAAGCUGUGtt (SEQ ID NO: 146)	CACAGCUUAACCUGUCCUCtt (SEQ ID NO: 147)
P14KB	GCUACGGAAGCUGAUCCUCtt (SEQ ID NO: 148)	GAGGAUCAGCUUCCGUAGCtt (SEQ ID NO: 149)
FLT4	GUACGGCAACCUCUCCAACtt (SEQ ID NO: 150)	GUUGGAGAGGUUGCCGUACtt (SEQ ID NO: 151)
PSKH1	GAACCUGCACCGCUCCAAtt (SEQ ID NO: 152)	UAUGGAGCGGUGCAGGUUCtt (SEQ ID NO: 153)
PSKH1seq2 <sup>1</sup>	UUGGCCGAGGCAGCUUCAGtt (SEQ ID NO: 154)	CUGAACGCCUCGGCCAAtt (SEQ ID NO: 155)
ITPKC	GUCCUGGGCUGAUACCUCtt (SEQ ID NO: 156)	GAGGUUAUCAGCCCAGGACtt (SEQ ID NO: 157)
ROCK	UACAUGCCUGGUGGAGAUAtt (SEQ ID NO: 158)	GAUCUCCACCAGGCAUGUAtt (SEQ ID NO: 159)
BAI2	GCUCUGCAGUAUGGCUGCCtt (SEQ ID NO: 160)	GGCAGCCAUACUGCAGAGCtt (SEQ ID NO: 161)
ULK1	UUCUGUCUACCUGGUUAUGtt (SEQ ID NO: 162)	CAUAACCAGGUAGACAGAAtt (SEQ ID NO: 163)
DAGK	GAUCGUGCAGAUGAGUAACtt (SEQ ID NO: 164)	GUUACUCAUCUGCACGAUCtt (SEQ ID NO: 165)
STK6	GCCGGUUCAGAAUCAGAAAGtt (SEQ ID NO: 166)	CUUCUGAUUCUGAACCGGCtt (SEQ ID NO: 167)
FLJ13551	CACCAAUUAGUUCAAAGCtt (SEQ ID NO: 168)	AGCUUUGAACUAAUUGGUGtt (SEQ ID NO: 169)
GPR12	AGCGCUCUGUCUCAUUUGCtt (SEQ ID NO: 170)	GAAAUGAGACAGAGCGCUtt (SEQ ID NO: 171)
UK	AGCGCAAGACACUCUGUGGtt (SEQ ID NO: 172)	CCACAGAGUGCUUGCGCUtt (SEQ ID NO: 173)